Low Rates of HCV treatment among eligible injection drug users

HIV Treatment Bulletin - Vol. 8, No. 6/7, June-July 2007

Most HCV-positive IDUs do not receive HCV treatment. M Sulkowski and co-workers from Johns Hopkins in the US presented findings from a study to determine the proportion of HIV-positive and HIV-negative IDUs (former and active) in their programme who are eligible for and initiate HCV therapy with pegylated interferon (pegINF) + ribavirin (RBV) in the absence of geographic and financial barriers (treatment was offered free and on-site).

The study enrolled 332 subjects (172 HIV/HCV co-infected; 158 HCV mono-infected). HIV-co-infected IDUs were younger (41 to <44 years) and were more likely to be African American (90% to >74%), have a monthly income >$500 (52% to >23%) than those with HCV alone. The investigators reported no difference in the prevalence of mental illness (~64%), alcohol use (~20%), or interest in receiving HCV treatment (~93%).

HIV-co-infected IDUs were more likely to have detectable HCV RNA (20/172 HIV/HCV co-infected, 11%; 29/143 of HCV mono-infected, 20%; p <0.001) and less likely to be eligible for HCV treatment (75/152 of HIV/HCV, 49%; 78 /114 HCV, 68%; p = 0.002). Reasons given for ineligibility were: severe depression (HIV/HCV 12%; HCV 30%); life expectancy <2 years (HIV/HCV 40%; HCV 30%); hematologic abnormality (HIV/HCV 49%; HCV 22%); renal insufficiency (HIV/HCV 10%; HCV 8%). Of the treatment-eligible IDUs, ~40% initiated HCV therapy, defined as at least pegINF injection (31/75 HIV/HCV, 41%; 27/80 HCV, 36%).

The investigators concluded: “While ~50% of HIV/HCV-co-infected IDUs were ineligible for HCV treatment, most (~80%) of HCV-mono-infected IDUs were treatment-eligible. Despite the removal of financial and geographic barriers, only ~40% of treatment-eligible IDUs initiated HCV treatment. Strategies are needed to increase HCV treatment uptake among IDUs.”

Ref: Sulkowski M, S Mehta S, Moore R et al. Low rates of HCV therapy among treatment-eligible injection drug users with and without HIV Co-infection. 14th CROI, 2007, Los Angeles. Poster abstract 947.

2007-06-10
IB070806-16

©2007. I-BASE HIV Treatment Bulletin. Permission to reproduce courtesy of HIV i-Base, Third Floor East, Thrale House, 44-46 Southwark Street, London SE1 1UN - T: +44 (0) 20 7407 8488 F: +44 (0) 20 7407 8489

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted grants from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, the National Library of Medicine, and donations from users like you. Always watch for outdated information. This article first appeared in 2007. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 2007. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content.